StockData
Cingulate Inc. logo

Cingulate Inc. (CING) stock

CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.72+0.97 (+25.87%)

Close on Nov 17, 2026Market cap $68.64MP/E –Yield –

Cingulate net income

Net income is the profit left for shareholders after every expense, interest and tax.

Cingulate's net income for the twelve months ending Jun 30, 2026 was -$28.80M. For fiscal 2025 it was -$22.45M. The highest annual figure on record is -$7.18M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.45M–
FY2024Dec 31, 2024-$16.56M–
FY2023Dec 31, 2023-$23.53M–
FY2022Dec 31, 2022-$17.68M–
FY2021Dec 31, 2021-$20.71M–
FY2020Dec 31, 2020-$7.18M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.87M–
Q1 FY2026Mar 31, 2026-$9.31M–
Q4 FY2025Dec 31, 2025-$6.27M–
Q3 FY2025Sep 30, 2025-$7.34M–
Q2 FY2025Jun 30, 2025-$4.98M–
Q1 FY2025Mar 31, 2025-$3.85M–
Q4 FY2024Dec 31, 2024-$6.23M–
Q1 FY2024Mar 31, 2024-$2.97M–
Q4 FY2023Dec 31, 2023-$6.93M–
Q3 FY2023Sep 30, 2023-$5.98M–
Q2 FY2023Jun 30, 2023-$6.62M–
Q1 FY2023Mar 31, 2023-$4.00M–
Q4 FY2022Dec 31, 2022-$4.61M–
Q3 FY2022Sep 30, 2022-$4.03M–
Q2 FY2022Jun 30, 2022-$4.04M–
Q1 FY2022Mar 31, 2022-$5.00M–
Q4 FY2021Dec 31, 2021-$2.65M–
Q3 FY2021Sep 30, 2021-$15.29M–
Q2 FY2021Jun 30, 2021-$1.43M–
Q1 FY2021Mar 31, 2021-$1.33M–

More Cingulate figures

See a number that looks wrong?